Phase 3 Clinical Study of AK112 for NSCLC Patients

NCT05184712 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

322

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-small Cell Lung Cancer

Interventions

DRUG: Ivonescimab (SMT112 or AK112) Injection
DRUG: Placebo Injection

Sponsor

Akeso